Tag: pazopanib

1. In patients with advanced, platinum-resistant ovarian cancer, combination therapy of a tyrosine kinase inhibitor, pazopanib, with paclitaxel significantly increased progression-free survival compared to paclitaxel alone. 2. Patients who received pazopanib plus paclitaxel suffered from higher rates of serious side effects including neutropenia, leucopenia, and hypertension. Evidence Rating Level: 2 (Good) Study...
Image: PD  1. Pazopanib and sunitinib showed similar efficacy in treating metastatic renal-cell carcinoma as a first-line therapy.  2. Quality-of-life measures generally favored pazopanib. Toxicity profiles were mixed.  Evidence Rating Level: 2 (Good)             Study Rundown: This study demonstrated that pazopanib has more favorable quality-of-life outcomes compared to sunitinib...